Data / Drug companies / Civica, Inc.
Civica, Inc.: 103 products in the FDA NDC directory, labeler code 72572
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Civica, Inc. (labeler code 72572) lists 103 products in the FDA National Drug Code Directory, covering 61 finished drugs by generic name. By type: 103 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 9, 2026.
The request: Watch Civica, Inc. (FDA labeler code 72572): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72572
- Products in commercial distribution
- 103
- Packages
- 105
- Finished drugs by generic name
- 61
- Prescription products
- 103
- Over the counter products
- 0
- Controlled substance products
- Schedule II 4, Schedule III 2, Schedule IV 5
- Flagged as original packager
- 94 of 94 products that carry the flag
- Started marketing in the last 12 months
- 12
- Products with a marketing end date set
- 3
- Earliest marketing start
- June 16, 1975
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 82 | 79.6% |
| New drug applications (NDA) | 18 | 17.5% |
| Biologics (BLA) | 2 | 1.9% |
| Authorized generics (NDA) | 1 | 1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 103 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 39 | 37.9% |
| Injection, solution | 28 | 27.2% |
| Injection, powder, for solution | 19 | 18.4% |
| Injection, powder, lyophilized, for solution | 10 | 9.7% |
| Injection, emulsion | 3 | 2.9% |
| Injection, solution, concentrate | 3 | 2.9% |
| Solution | 1 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Diazepam | 72572-175 | Injection | Generic drugs (ANDA) | September 9, 2026 |
| Cefazolin | 72572-054 | Injection, powder, for solution | New drug applications (NDA) | August 18, 2026 |
| Bumetanide | 72572-211 | Injection, solution | Generic drugs (ANDA) | August 1, 2026 |
| Bumetanide | 72572-210 | Injection, solution | Generic drugs (ANDA) | August 1, 2026 |
| Furosemide | 72572-275 | Injection | New drug applications (NDA) | July 13, 2026 |
| Sodium Bicarbonate | 72572-200 | Solution | Generic drugs (ANDA) | June 10, 2026 |
| Ketorolac Tromethamine | 72572-357 | Injection, solution | Generic drugs (ANDA) | April 1, 2026 |
| Ketorolac Tromethamine | 72572-356 | Injection, solution | Generic drugs (ANDA) | April 1, 2026 |
| Methylprednisolone Sodium Succinate | 72572-098 | Injection, powder, for solution | Generic drugs (ANDA) | December 1, 2025 |
| Methylprednisolone Sodium Succinate | 72572-097 | Injection, powder, for solution | Generic drugs (ANDA) | December 1, 2025 |
| Daptomycin | 72572-158 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | November 28, 2025 |
| Vancomycin Hydrochloride | 72572-029 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 10, 2025 |
| Enoxaparin Sodium | 72572-280 | Injection | Generic drugs (ANDA) | November 1, 2025 |
| Insulin glargine | 72572-424 | Injection, solution | Biologics (BLA) | October 30, 2025 |
| Insulin glargine | 72572-422 | Injection, solution | Biologics (BLA) | October 30, 2025 |
| Vasopressin | 72572-860 | Injection, solution | New drug applications (NDA) | October 22, 2025 |
| Vancomycin Hydrochloride | 72572-207 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 13, 2025 |
| Vancomycin Hydrochloride | 72572-105 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 13, 2025 |
| Piperacillin and tazobactam | 72572-418 | Injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
| Piperacillin and tazobactam | 72572-414 | Injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
| Meropenem | 72572-412 | Injection | Generic drugs (ANDA) | September 8, 2025 |
| Meropenem | 72572-410 | Injection | Generic drugs (ANDA) | September 8, 2025 |
| Ampicillin sodium and sulbactam sodium | 72572-136 | Injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
| Ampicillin sodium | 72572-094 | Injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
| Ampicillin sodium | 72572-093 | Injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.